YOLFTbeta
Feng Chi Biotech Corp.

Feng Chi Biotech Corp.

6744 · TWO · Healthcare / Biotechnology

13.05TWD-0.05 (-0.38%)

Price History

Full chart

Market Stats

Previous Close13.10
Open13.00
Day Range12.60 – 13.05
52-Week Range12.61 – 19.24
Volume14.00K
Market Cap221.76M
P/E (TTM)22.50
Forward P/E0.00
EPS0.64
Dividend Yield5.83%
Beta0.29
50-Day Avg14.54
200-Day Avg15.90

About

Feng Chi Biotech Corp. engages in the wholesale and retail of medical devices and precision instruments and biotechnology services in Taiwan and internationally. The company provides preimplantation genetic testing, prenatal testing, precision medicine, newborn screening, food/pharmaceutical microbiological testing, and medical translational research services, as well as infectious disease detection services. It also distributes various genetic and medical testing services. The company was founded in 1992 and is based in Taipei, Taiwan.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOHong-Ming Zhang
  • Headquarters1, No.5, Shaoxing North Street, Taipei, Taiwan, 100, Taiwan
  • Websitehttps://www.fcbiotech.com.tw

Leadership

  • Hong-Ming ZhangChairman, GM & Manager
  • Mei-Zhen LuAccounting Supervisor

Financials

Income Statement

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue174.33M178.91M182.57M193.46M180.58M171.10M177.36M
Growth (%)-+2.63%+2.05%+5.96%-6.66%-5.25%+3.66%
Cost of Revenue102.08M92.98M96.46M110.02M100.98M93.95M98.20M
Gross Profit72.25M85.92M86.11M83.44M79.60M77.15M79.16M
Gross Margin41.44%48.03%47.16%43.13%44.08%45.09%44.63%
Operating Expense52.15M57.34M59.66M56.38M55.44M61.03M65.31M
Operating Income20.10M28.58M26.44M27.07M24.16M16.12M13.85M
Operating Margin11.53%15.98%14.48%13.99%13.38%9.42%7.81%
EBITDA27.59M39.88M36.96M36.79M34.84M29.80M29.24M
EBITDA Margin15.83%22.29%20.24%19.02%19.29%17.42%16.48%
Net Income17.36M25.39M23.14M24.61M22.79M16.59M14.47M
Net Income Margin9.96%14.19%12.67%12.72%12.62%9.70%8.16%
R&D12.95M11.91M14.19M12.09M13.10M14.60M13.50M
R&D as % of Total Revenue7.43%6.66%7.77%6.25%7.25%8.53%7.61%
Interest Expense17.00K167.00K98.00K58.00K325.00K254.00K181.00K
Interest Expense % of Total Revenue0.01%0.09%0.05%0.03%0.18%0.15%0.10%

Balance Sheet

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets267.32M283.99M286.69M308.36M301.03M299.07M287.91M
Total Liabilities53.77M58.91M56.18M72.49M63.03M59.19M48.01M
Total Equity213.55M225.08M230.51M235.87M238.00M239.88M239.90M
Cash40.24M47.27M48.80M65.90M30.61M26.25M17.39M
Total Debt7.91M5.26M2.55M13.48M10.80M8.15M-
Net Debt-32.33M-42.01M-46.26M-52.42M-19.81M-18.10M-

Cash Flow

Currency: TWD2019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow23.61M39.28M32.92M28.49M15.41M25.05M3.24M
Investing Cash Flow-86.26M-15.74M-10.97M10.62M-27.34M-10.60M-
Financing Cash Flow18.86M-16.50M-20.42M-22.01M-23.37M-18.82M-
Capital Expenditure4.42M3.07M1.09M260.00K1.40M14.59M13.13M
Free Cash Flow19.18M36.22M31.83M28.23M14.02M10.46M-9.89M
Dividends Paid13.22M13.86M17.71M19.25M20.79M16.17M14.63M
FCF to OCF81.26%92.19%96.67%99.09%90.95%41.74%-305.62%
Dividend Paid to FCF68.92%38.27%55.64%68.19%148.29%154.65%-147.93%

Key Statistics & Ratios

Market Cap221.76M
Enterprise Value57.03M
Trailing P/E22.50
Forward P/E0.00
Price / Sales1.41
Price / Book0.98
EPS0.64
Book Value14.90
Revenue (TTM)156.99M
Gross Profit (TTM)70.45M
EBITDA16.98M
Profit Margin6.31%
Operating Margin4.55%
Return on Equity4.28%
Return on Assets1.52%
Shares Outstanding15.40M
Shares Float5.20M
Beta0.29
Dividend Yield5.83%
Dividend Rate0.84
Payout Ratio147.67%

Dividends

20261×
0.84Jul 21, 2026
20251×
0.95Jul 22, 2025
20241×
1.05Jul 22, 2024
20231×
1.35Jul 20, 2023
20221×
1.25Jul 4, 2022
20211×
1.15Jul 27, 2021
20201×
0.90Jul 21, 2020